Results 61 to 70 of about 4,863 (192)

Effects of Siltuximab Versus Corticosteroids in Preventing COVID−19 Pneumonia Disease Progression: Multicentre, Open‐Label, Randomized Clinical Trial

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT In 2020, COVID‐19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open‐label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID‐19 ...
Lorna Leal, María del Puerto Bernoy González, Clara Castán, Fernanda Meira, Gerard Dueñas, Judit Pich, Marta Hernández‐Meneses, Verónica Rico, Nicole García‐Pouton, Daiana Agüero, Elisa de Lazzari, Adrià Tomé, Sabina Herrera, José Muñóz, Alex Almuedo, Sergio Prieto‐González, Pedro Castro, Maria Angeles Marcos, Montse Tuset, Roger Paredes, Cristina Carbonell, David Dalmau, José Antonio Martínez, Alex Soriano, Felipe García, SILCOR study group, A. Moreno, M. Solá, A. Ugarte, A. Gonzalez‐Cordón, M. Laguno, J. Rojas, B. Torres, J. Ambrosioni, L. Morata, C. García‐Vidal, C. Cardozo, M. Bodro, M. Chumbita, L. de la Mora, A. Inciarte, P. Puerta‐Alcalde, A. del Rio, S. Fernandez, A. Tellez, D. Camprubi, M. T. de Alba, M. Fernandez, E. Ferrer, B. Grau, H. Marti, M. Muelas, M. J. Pinazo, N. Rodriguez, A. Aldea, J. Calvo, A. Capdevila, I. Carbonell, A. Foncillas, M. Feliu, C. Gabara, I. Grafia, A. Ladino, A. López‐Soto, A. Matas, J. Marco‐Hernández, P. Moreno, J. Naval, J. Padrosa, M. Pellicé, J. Ribot, O. Rodríguez‐Núnez, F. Seguí, H. Ventosa, C. Zamora‐Martínez, M. Alvarez, E. Rubio, A. Vergara   +77 more
wiley   +1 more source

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Experimental Hematology & Oncology, 2021
Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the treatment of CRS.
Lina Zhang, Shuai Wang, Ji Xu, Run Zhang, Han Zhu, Yujie Wu, Liying Zhu, Jianyong Li, Lijuan Chen   +8 more
doaj   +1 more source

Targeting microenvironment in cancer therapeutics [PDF]

, 2016
During development of a novel treatment for cancer patients, the tumor microenvironment and its interaction with the tumor cells must be considered. Aspects such as the extracellular matrix (ECM), the epithelial-mesenchymal transition (EMT), secreted ...
Lu, Tao, Martin, Matthew, Wei, Han
core   +2 more sources

Review of siltuximab in the treatment of multicentric Castleman’s disease [PDF]

Therapeutic Advances in Hematology, 2016
Castleman’s disease (CD) is a rare lymphoproliferative disorder that has multiple histologic patterns, as well as two distinct clinical forms: unicentric or multicentric. Multicentric Castleman’s disease (MCD) may have mild symptoms in some cases, but in others it can progress to severe pancytopenia, life-threatening infection, secondary malignancy ...
Shayna, Sarosiek, Ruchit, Shah, Nikhil C, Munshi   +2 more
openaire   +2 more sources

Snapshot Look at Castleman Disease

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Castleman disease (CD) is a rare and heterogeneous group of lymphoproliferative disorders characterised by abnormal proliferation of lymphoid tissue. First described in the 1950s, it has since been classified into two major clinical forms: unicentric CD (UCD), involving a single lymph node region and multicentric CD (MCD), which affects ...
Ciprian Jitaru, Natalia Zlampa, Delia Dima, Anca Bojan, Mihnea Zdrenghea, Laura Urian, David Kegyes, Anamaria Bancos, Maria Santa, Andrei Ivancuta, Bobe Petrushev, Madalina Nistor, Bogdan Tigu, Catalin Constantinescu, Bogdan Fetica, Maria Puiu, Mihai‐Stefan Muresan, Ciprian Tomuleasa   +17 more
wiley   +1 more source

Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome

Frontiers in Immunology, 2021
Recently, a novel disorder coined VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome was identified in patients with adult-onset inflammatory syndromes, often accompanied by myelodysplastic syndrome1.
Frederik Staels, Frederik Staels, Albrecht Betrains, Albrecht Betrains, F. J. Sherida H. Woei-A-Jin, F. J. Sherida H. Woei-A-Jin, Nancy Boeckx, Nancy Boeckx, Marielle Beckers, Marielle Beckers, An Bervoets, An Bervoets, Mathijs Willemsen, Mathijs Willemsen, Barbara Neerinckx, Barbara Neerinckx, Stephanie Humblet-Baron, Daniel Engelbert Blockmans, Daniel Engelbert Blockmans, Steven Vanderschueren, Steven Vanderschueren, Rik Schrijvers, Rik Schrijvers, Rik Schrijvers   +23 more
doaj   +1 more source

Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. [PDF]

, 2015
BackgroundKetoconazole is a well-known CYP17-targeted systemic treatment for castration-resistant prostate cancer (CRPC). However, most of the published data has been in the pre-chemotherapy setting; its efficacy in the post-chemotherapy setting has not ...
Beckett, LA, Lara, PN, Lo, EN, Pan, CX, Robles, D, Sands, JM, Suga, JM   +6 more
core  

Siltuximab (CNTO 328): a promising option for human malignancies

Drug Design, Development and Therapy, 2015
Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 (IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of siltuximab in the treatment of human malignancies. We also
Chen R, Chen B
openaire   +4 more sources

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapies have revolutionized the treatment of hematological malignancies, achieving high response rates in patients with relapsed or refractory disease. Despite these benefits, CAR‐T cell therapies are associated with unique toxicities, including cytokine release syndrome (CRS), immune effector cell ...
Livia Donzelli, Veronica Zullino, Giovanni Fernando Torelli, Maria Stefania De Propris, Mario Piazzolla, Franco Ruberto, Maurizio Martelli, Alice Di Rocco   +7 more
wiley   +1 more source

Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy

eJHaem, 2022
Immune effector cell‐associated neurotoxicity syndrome (ICANS) is a frequent adverse event after Chimeric antigen receptor T cells (CAR‐T cells). A patient treated with anti‐CD19 CAR‐T cells for a refractory mantle cell lymphoma presented at Day 8 post ...
Baptiste Le Calvez, Marion Eveillard, Paul Decamps, Jesus Aguilar, Amélie Seguin, Emmanuel Canet, Audrey Grain, Cyrille Touzeau, Benoît Tessoulin, Thomas Gastinne   +9 more
doaj   +1 more source